Novavax, Inc. (NASDAQ:NVAX) Position Reduced by Banco Bilbao Vizcaya Argentaria S.A.

Banco Bilbao Vizcaya Argentaria S.A. trimmed its position in Novavax, Inc. (NASDAQ:NVAX) by 22.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 60,508 shares of the biopharmaceutical company’s stock after selling 17,099 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Novavax were worth $479,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Spire Wealth Management bought a new stake in shares of Novavax in the 4th quarter worth approximately $29,000. New Age Alpha Advisors LLC bought a new position in shares of Novavax in the fourth quarter valued at $35,000. KBC Group NV lifted its position in shares of Novavax by 97.0% during the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock valued at $64,000 after acquiring an additional 3,917 shares during the last quarter. TigerOak Management L.L.C. acquired a new stake in shares of Novavax during the 4th quarter valued at $86,000. Finally, AlphaQuest LLC boosted its stake in shares of Novavax by 290.1% during the 4th quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 7,940 shares in the last quarter. 53.04% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on NVAX. TD Cowen raised Novavax to a “hold” rating in a report on Thursday, February 27th. BTIG Research initiated coverage on shares of Novavax in a research note on Friday, February 28th. They set a “buy” rating and a $19.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $18.00.

Novavax Trading Up 0.4 %

Shares of Novavax stock opened at $6.70 on Tuesday. Novavax, Inc. has a 1 year low of $4.10 and a 1 year high of $23.86. The company has a market cap of $1.08 billion, a P/E ratio of -2.96, a P/E/G ratio of 2.85 and a beta of 3.15. The stock has a 50-day moving average price of $7.10 and a 200 day moving average price of $8.28.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.24. The company had revenue of $88.31 million during the quarter, compared to analysts’ expectations of $85.48 million. During the same period last year, the company earned ($1.44) earnings per share. On average, equities analysts forecast that Novavax, Inc. will post -1.46 earnings per share for the current fiscal year.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.